Radiological biomarkers for assessing response to locoregional therapies in hepatocellular carcinoma: From morphological to functional imaging (Review).
Radiological biomarkers for assessing response to locoregional therapies in hepatocellular carcinoma: From morphological to functional imaging (Review).
复制标题
DOI：
10.3892/or.2017.5420
复制
发表时间：
2017-03
期刊：
影响因子：
4.2
通讯作者：
X. Ye;Zuguo Yuan;Jian Zhang;Zheng Yuan
中科院分区：
文献类型：
--
作者：
X. Ye;Zuguo Yuan;Jian Zhang;Zheng Yuan
许多肝细胞癌（HCC）患者没有资格接受根治性外科干预，而是接受局部区域治疗（LRT），包括消融和血管内治疗。影像学反应评估在HCC的管理中是必不可少的，以确定治疗的疗效，并作为改善生存率的替代标志物。用于肿瘤负荷测量的已建立的形态学图像生物标志物继续应用，因为尺寸测量可以容易地用于临床实践。然而，在肝定向LRT治疗HCC的背景下，简单的肿瘤形态学变化可能信息量较少，通常比生物学变化晚出现。功能成像（如灌注和扩散成像，PET-CT/MR和MR波谱）有可能成为评估HCC对LRT反应的有前景的技术。虽然有希望，但这些功能性成像生物标志物中没有一个经过标准化和验证的所有必要步骤，并建立了临床实践的可接受标准。
Many hepatocellular carcinoma (HCC) patients do not qualify for curative surgical intervention and are instead treated with locoregional therapies (LRTs) including ablative and endovascular therapies. Assessment of imaging response is essential in the management of HCC for determining efficacy of therapy and as a surrogate marker for improved survival. The established morphological image biomarkers for tumor burden measurement continue to be applied, as size measurement can easily be used in clinical practice. However, in the setting of liver-directed LRTs for HCC, simple tumor morphological changes can be less informative and usually appear later than biologic changes. Functional imaging (such as perfusion and diffusion imaging, PET-CT/MR and MR spectroscopy) has the potential to be a promising technique for assessment of HCC response to LRTs. Although promising, none of these functional imaging biomarkers have gone through all the required steps of standardization and validation and established accepted criteria for clinical practice.